| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2014PLoSO...9j1737P |
| P356 | DOI | 10.1371/JOURNAL.PONE.0101737 |
| P932 | PMC publication ID | 4105459 |
| P698 | PubMed publication ID | 25047634 |
| P5875 | ResearchGate publication ID | 264126558 |
| P50 | author | Jean-Francois Trape | Q21340358 |
| Odile Mercereau-Puijalon | Q28322958 | ||
| Cheikh Sokhna | Q61809634 | ||
| Adama Tall | Q80329231 | ||
| Ronald Perraut | Q88302312 | ||
| Laurence Marrama | Q94553982 | ||
| Charlotte Joos | Q114440096 | ||
| Hannah E J Polson | Q114440097 | ||
| Shirley Longacre | Q114440098 | ||
| P2093 | author name string | Vincent Richard | |
| P2860 | cites work | Immune mechanisms in malaria: new insights in vaccine development | Q21032484 |
| Artemisinin Resistance in Plasmodium falciparum Malaria | Q22061852 | ||
| The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate | Q27618095 | ||
| Crystal structure of a Fab complex formed with PfMSP1-19, the C-terminal fragment of merozoite surface protein 1 from Plasmodium falciparum: a malaria vaccine candidate | Q27641117 | ||
| Characterization of C-terminal merozoite surface protein-1 baculovirus recombinant proteins from Plasmodium vivax and Plasmodium cynomolgi as recognized by the natural anti-parasite immune response | Q56451852 | ||
| Rapid evaluation of malaria parasite density and standardization of thick smear examination for epidemiological investigations | Q69894647 | ||
| Rapid dissemination of Plasmodium falciparum drug resistance despite strictly controlled antimalarial use | Q28469104 | ||
| A phase 1 trial of MSP2-C1, a blood-stage malaria vaccine containing 2 isoforms of MSP2 formulated with Montanide® ISA 720 | Q28744696 | ||
| Invasion of red blood cells by malaria parasites | Q29618806 | ||
| Lack of sequence diversity in the gene encoding merozoite surface protein 5 of Plasmodium falciparum | Q30046901 | ||
| Long-term clinical protection from falciparum malaria is strongly associated with IgG3 antibodies to merozoite surface protein 3. | Q33305467 | ||
| Antibodies to Plasmodium falciparum and Plasmodium vivax merozoite surface protein 5 in Indonesia: species-specific and cross-reactive responses | Q33333604 | ||
| Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies | Q33548663 | ||
| Changing malaria epidemiology and diagnostic criteria for Plasmodium falciparum clinical malaria | Q34430949 | ||
| A field trial to assess a blood-stage malaria vaccine | Q35622737 | ||
| Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. | Q36368911 | ||
| Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children | Q36862490 | ||
| Identification and prioritization of merozoite antigens as targets of protective human immunity to Plasmodium falciparum malaria for vaccine and biomarker development | Q36984161 | ||
| Effect of the malaria vaccine Combination B on merozoite surface antigen 2 diversity | Q39006938 | ||
| Malaria morbidity and pyrethroid resistance after the introduction of insecticide-treated bednets and artemisinin-based combination therapies: a longitudinal study | Q39532443 | ||
| Combating malaria morbidity and mortality by reducing transmission | Q39532471 | ||
| Plasmodium falciparum- and merozoite surface protein 1-specific antibody isotype balance in immune Senegalese adults | Q39831592 | ||
| The rise and fall of malaria in a West African rural community, Dielmo, Senegal, from 1990 to 2012: a 22 year longitudinal study | Q40207794 | ||
| Soluble and glyco-lipid modified baculovirus Plasmodium falciparum C-terminal merozoite surface protein 1, two forms of a leading malaria vaccine candidate | Q40260804 | ||
| Evidence for an age-dependent pyrogenic threshold of Plasmodium falciparum parasitemia in highly endemic populations. | Q40668049 | ||
| Plasmodium falciparum: characterization of gene R45 encoding a trophozoite antigen containing a central block of six amino acid repeats | Q42601387 | ||
| Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes | Q42938913 | ||
| Evaluation of anti-Plasmodium falciparum antibodies in Senegalese adults using different types of crude extracts from various strains of parasite | Q43875328 | ||
| Four years' entomological study of the transmission of seasonal malaria in Senegal and the bionomics of Anopheles gambiae and A. arabiensis | Q44138511 | ||
| The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal | Q44171038 | ||
| Evaluation of immunogenicity and protective efficacy of carrier-free Plasmodium falciparum R23 antigen in pre-exposed saimiri sciureus monkeys | Q44273580 | ||
| Pattern of immunoglobulin isotype response to Plasmodium falciparum blood-stage antigens in individuals living in a holoendemic area of Senegal (Dielmo, west Africa). | Q44710649 | ||
| Opsonization as an effector mechanism in human protection against asexual blood stages of Plasmodium falciparum: Functional role of IgG subclasses | Q46370720 | ||
| Close linkage of three merozoite surface protein genes on chromosome 2 of Plasmodium falciparum | Q47751343 | ||
| Seasonal fluctuation of antibody levels to Plasmodium falciparum parasitized red blood cell-associated antigens in two Senegalese villages with different transmission conditions | Q47881790 | ||
| A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea | Q47901914 | ||
| Malaria-specific antibody subclasses in immune individuals: a key source of information for vaccine design. | Q47919936 | ||
| Gamma-globulin and acquired immunity to human malaria | Q47957467 | ||
| Distinct surrogate markers for protection against Plasmodium falciparum infection and clinical malaria identified in a Senegalese community after radical drug cure | Q47971699 | ||
| Antibodies to the conserved C-terminal domain of the Plasmodium falciparum merozoite surface protein 1 and to the merozoite extract and their relationship with in vitro inhibitory antibodies and protection against clinical malaria in a Senegalese vi | Q48000659 | ||
| Gene polymorphism of Plasmodium falciparum merozoite surface proteins 4 and 5. | Q48008142 | ||
| Malaria attacks in children exposed to high transmission: who is protected? | Q48017844 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | malaria | Q12156 |
| Plasmodium falciparum | Q311383 | ||
| P304 | page(s) | e101737 | |
| P577 | publication date | 2014-07-21 | |
| P1433 | published in | PLOS One | Q564954 |
| P1476 | title | Association of antibody responses to the conserved Plasmodium falciparum merozoite surface protein 5 with protection against clinical malaria | |
| P478 | volume | 9 |
| Q64086749 | A Synthetic Nanoparticle Based Vaccine Approach Targeting MSP4/5 Is Immunogenic and Induces Moderate Protection Against Murine Blood-Stage Malaria |
| Q63634462 | A defined mechanistic correlate of protection against Plasmodium falciparum malaria in non-human primates |
| Q36393772 | Analysis of antibody profiles in symptomatic malaria in three sentinel sites of Ivory Coast by using multiplex, fluorescent, magnetic, bead-based serological assay (MAGPIX™). |
| Q90723670 | Analysis of antibody responses to selected Plasmodium falciparum merozoite surface antigens in mild and cerebral malaria and associations with clinical outcomes |
| Q46471407 | Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria |
| Q37094412 | Co-circulation of Plasmodium and Bacterial DNAs in Blood of Febrile and Afebrile Children from Urban and Rural Areas in Gabon. |
| Q64086742 | Differential Patterns of IgG Subclass Responses to Antigens in Relation to Malaria Protection and RTS,S Vaccination |
| Q46222698 | Evaluating anti-disease immunity to malaria and implications for vaccine design. |
| Q89571059 | IgG antibody response against Plasmodium falciparum aminopeptidase 1 antigen in Gabonese children living in Makokou and Franceville |
| Q36621046 | Inflammatory cytokine and humoral responses to Plasmodium falciparum glycosylphosphatidylinositols correlates with malaria immunity and pathogenesis |
| Q40055186 | Merozoite Surface Protein 1 from Plasmodium falciparum Is a Major Target of Opsonizing Antibodies in Individuals with Acquired Immunity against Malaria |
| Q26772878 | Merozoite surface proteins in red blood cell invasion, immunity and vaccines against malaria |
| Q60946995 | Neutrophils and Malaria |
| Q92664225 | Plasmodium falciparum merozoite surface antigen-specific cytophilic IgG and control of malaria infection in a Beninese birth cohort |
| Q90464578 | Practical example of multiple antibody screening for evaluation of malaria control strategies |
| Q92599701 | RTS,S/AS01E immunization increases antibody responses to vaccine-unrelated Plasmodium falciparum antigens associated with protection against clinical malaria in African children: A case-control study |
Search more.